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Abstract
Objective To determine an optimal population red blood cell (RBC)
folate concentration for the prevention of neural tube birth defects.
Design Bayesian model.
Setting Data from two population based studies in China.
Participants 247 831 participants in a prospective community
intervention project in China (1993-95) to prevent neural tube defects
with 400 μg/day folic acid supplementation and 1194 participants in a
population based randomized trial (2003-05) to evaluate the effect of
folic acid supplementation on blood folate concentration among Chinese
women of reproductive age.
Intervention Folic acid supplementation (400 μg/day).
Main outcome measures Estimated RBC folate concentration at time
of neural tube closure (day 28 of gestation) and risk of neural tube
defects.
Results Risk of neural tube defects was high at the lowest estimated
RBC folate concentrations (for example, 25.4 (95% uncertainty interval
20.8 to 31.2) neural tube defects per 10 000 births at 500 nmol/L) and
decreased as estimated RBC folate concentration increased. Risk of
neural tube defects was substantially attenuated at estimated RBC folate
concentrations above about 1000 nmol/L (for example, 6 neural tube
defects per 10 000 births at 1180 (1050 to 1340) nmol/L). The modeled
dose-response relation was consistent with the existing literature. In
addition, neural tube defect risk estimates developed using the proposed
model and population level RBC information were consistent with the
prevalence of neural tube defects in the US population before and after
food fortification with folic acid.
Conclusions A threshold for “optimal” population RBC folate
concentration for the prevention of neural tube defects could be defined
(for example, approximately 1000 nmol/L). Population based RBC folate
concentrations, as a biomarker for risk of neural tube defects, can be
used to facilitate evaluation of prevention programs as well as to identify
subpopulations at elevated risk for a neural tube defect affected
pregnancy due to folate insufficiency.
Introduction
Clinical trials, community intervention programs, and food
fortification programs over the past decades have shown that
maternal folic acid intake before and during early pregnancy
reduces a woman’s risk of having a pregnancy affected by a
neural tube birth defect.1-3 Every year, an estimated 300 000 or
more pregnancies are affected by neural tube defects.4 To reduce
the substantial morbidity, mortality, and cost of these devastating
conditions, programs of staple food fortification with folic acid
have been adopted and have resulted in prevention of neural
tube defects in many countries (such as Chile, the United States,
Canada, Costa Rica, and South Africa).5-9 All public health
recommendations in the United States for prevention of neural
tube defects are based on suggested levels for dietary intake of
folate/folic acid (for example, 400 μg/day).10 However,
estimating natural intake of folate from food is difficult,
expensive, and imprecise, as it requires large population based
surveys that rely on self reported dietary recall. A reliable
biomarker (such as red blood cell or serum folate concentrations)
would be useful for evaluating the potential public health impact
of prevention programs for neural tube defects. Existing
definitions of clinical folate deficiency (<340 nmol/L red blood
cell folate concentrations and <10 nmol/L serum folate
concentrations)11 are not based on folate sufficiency for the
prevention of neural tube defects, so existing cut-off values are
inappropriate for use in efforts to prevent neural tube defects.
Folate sufficiency or optimal blood folate concentrations that
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are directly linked to risk of neural tube defects are needed and
could be used as a benchmark to enhance the biomarker based
monitoring of prevention efforts and as a tool for needs
assessments of such efforts (for example, implementing or
modifying fortification programs).
The exact mechanism by which maternal consumption of
periconceptional folic acid prevents some neural tube defects
(“folate sensitive” neural tube defects) remains uncertain.12-14
However, many studies have shown increases in both red blood
cell and serum/plasma folate concentrations in response to
increased folic acid intake 15-23 (fig 1⇓). Genetic variation in
folate metabolism due to a single nucleotide polymorphism at
the methylene tetrahydrofolate reductase (MTHFR) gene (667
C to T transition) has also been shown to be associated with
reduced red blood cell folate concentrations for a given intake
of folic acid (the synthetic form of folate used in foods and
supplements)24 and with increased risk of neural tube defects
across studies.25 26
Although the effects of folic acid intake on risks of neural tube
defects are well established,1 2 5-7 27 only one study has directly
described differences in the risk of having a child with a neural
tube defect across a range of maternal red blood cell folate
concentrations.28A single case-control study in Ireland (1986-90)
assessed the association between maternal red blood cell folate
concentration measured during early pregnancy (median
gestational age 15weeks; 84 cases, 266 controls) and subsequent
risk of neural tube defects.28 In this study, Daly and colleagues
observed a very high risk of neural tube defects at lower
concentrations of red blood cell folate (<340 nmol/L: risk of 66
per 10 000 births) and substantially mitigated risk at
concentrations above a cut-off concentration of 906 nmol/L (8
neural tube defects per 10 000 births; mean 1292 nmol/L).28
Whether findings from this single study in Ireland are
generalizable to other populations with different micronutrient
intakes or racial/ethnic backgrounds is unclear. Moreover, as 8
neural tube defects per 10 000 births could still be considered
a moderately high risk population, additional data above the
906 nmol/L cut-off concentration for red blood cell folate are
needed to examine the possibility of further risk reductions at
higher red blood cell folate concentrations.
To investigate this question, we used existing data sources to
assess the potential association between red blood cell folate
concentrations at the time of neural tube closure (embryologic
day 28) and risk of neural tube defects among participants in
the Community Intervention Project (China 1993-95; n=247
831).1 15 24 29-31 We then compared the estimated association
developed in this analysis with that observed in the Irish
population reported by Daly and colleagues.28We also used the
modeled association to predict risk of neural tube defects in the
US population before and after fortification from published
population based distributions of red blood cell folate
concentrations. Finally, we used the results of our analysis to
derive candidate red blood cell folate concentrations for the
prevention of folate sensitive neural tube defects.
Methods
Study populations
Two study populations contributed data to this study
(supplementary table A): the Community Intervention Project
and the Folic Acid Dosing Trial. The Community Intervention
Project was a population based cohort study of a public health
campaign conducted in northern (Hebei Province) and southern
(Zhejiang and Jiangsu Provinces) regions of China from 1993
through 1995. Women were encouraged to consume 400 μg of
folic acid a day when planning pregnancy through the end of
the first trimester; the results of an analysis comparing the risk
of neural tube defects in women in this study who took folic
acid supplements with that in those who did not have been
previously described.1 In short, all women who were planning
a pregnancy or undergoing mandatory premarital examinations
were enrolled in a pregnancymonitoring system and were asked
to purchase bottles of folic acid supplements (31 pills, 400 µg)
and consume one folic acid supplement a day through the end
of the first trimester.1 Health workers recorded the dates that
the women started and stopped taking folic acid supplements,
the number of pills remaining in the bottles at the end of each
month as a measure of pill taking compliance, and the dates of
the women’s menstrual periods.1 Infants and fetuses with all
types of neural tube defects (that is, anencephaly,
craniorachischisis, iniencephaly, spina bifida, and encephalocele)
were ascertained through a birth defects surveillance system
that collected information on all live and stillborn infants (>20
weeks’ gestation) and those pregnancies terminated at any
gestation after the detection of a birth defect.1
In the analyses presented here, we included women if enough
information was collected to enable the estimation of red blood
cell folate concentration at the time of neural tube closure
(embryologic day 28, calculated by firstly adding 14 days to
the date of the start of the last menstrual period recorded by the
health workers (estimated date of conception) plus another 28
days for completion of neural tube closure (supplementary table
A). We included women who fulfilled the following criteria:
the woman became pregnant during the study period; the
outcome of the pregnancy was known (including still births and
pregnancy terminations for birth defects); folic acid supplement
taking status was known (yes v no); and, for those who took
folic acid supplements, the start and stop dates were recorded.
Women who started taking pills but stopped before becoming
pregnant were excluded from the analyses owing to insufficient
data for estimation of red blood cell folate concentrations at the
time of neural tube closure (supplementary figure A).
The second study, the Folic Acid Dosing Trial randomized trial
(registered at clinicaltrials.gov: NCT00207558), was conducted
in the northern Chinese province of Hebei from 2003 to 2005.15 24
Requirements for participation in the Folic Acid Dosing Trial
included to not be pregnant or breastfeeding and to have an
intrauterine device for contraception; to have no plans to become
pregnant within nine months of recruitment into the trial; to live
in the township; to have a child aged 2-4 years; to have had no
folic acid supplement use within the previous three months; and
to have no current prescription drug use.15 24 Foods fortified with
folic acid were not available in China at the time, so study
participants were not exposed to dietary sources of folic acid.
Enrolled women were excluded from further participation and
were referred for medical treatment if they were either vitamin
B12 deficient (plasma vitamin B12<148 pmol/L) or anemic
(hemoglobin<120 g/L); however, baseline folate concentrations
andMTHFR genotypes (n=1194) were measured for all enrolled
women (supplementary figure B).15 24 Randomized participants
were given weekly blister packs with four pills a day (folic acid
or placebo as appropriate) and assigned to dosage regimens of
100 µg/day, 400 µg/day, 4000 µg/day, or 4000 µg/week. Red
blood cell folate concentrations and MTHFR genotyping was
performed on all available samples, as previously reported.15 24 32
Fasting blood samples were collected at enrollment and after
one, three, and six months of supplementation. In the analysis
presented here, we used information only from Folic Acid
Dosing Trial participants who consumed 400 µg/day folic acid
(either 400 µg once a day or 100 µg four times a day; n=323)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4554 doi: 10.1136/bmj.g4554 (Published 29 July 2014) Page 2 of 12
RESEARCH
and had MTHFR genotype information (supplementary figure
B).15 24
General modeling strategy
The goal of this analysis was to estimate the association between
a mother’s red blood cell folate concentration at the time of her
fetus’s neural tube closure and the risk of a neural tube defect.
The primary data source for the analysis was the Community
Intervention Project, a public health campaign conducted in
China in the northern province of Hebei and the southern
provinces of Zhejiang and Jiangsu to reduce the risk of neural
tube defects by encouraging daily maternal periconceptional
consumption of 400 µg of folic acid.1 This study provided
information on the length of time that participants consumed
daily folic acid supplements before pregnancy and the neural
tube defect outcomes among 228 456 live births and fetal deaths,
but measurements of red blood cell folate concentration at the
time of neural tube closure and the mother’sMTHFR genotype
were not collected. However, data from one daily dosage of the
Folic Acid Dosing Trial, which was conducted on a sample of
women from the northern province of Hebei, provided
information on both red blood cell folate concentrations at zero,
one, three, and six months of 400 µg/day of folic acid
supplementation and MTHFR genotype (supplementary figure
C).24 Using data from the Folic Acid Dosing Trial, we modeled
the association between the length of time women consumed
folic acid and their resulting red blood cell folate concentrations,
including the effect of genotype on that association. We then
used this model to estimate red blood cell folate concentrations
for Community Intervention Project participants on the basis
of their reported pill consumption, enabling an evaluation of
the association between the estimates of red blood cell folate
concentrations and risk of neural tube defects.
The fact that MTHFR genotype was not determined for
Community Intervention Project participants and that genotype
can significantly affect the estimation of red blood cell folate
concentrations necessitated development of additional models
to estimate the distribution of genotypes among the Community
Intervention Project participants.We adjusted baseline red blood
cell folate concentrations for known differences in red blood
cell folate concentrations and MTHFR genotype distributions
in northern and southern China (supplementary table B).29-31As
a result, our analysis of the association between red blood cell
folate concentration and risk of neural tube defects among the
Community Intervention Project study population required
development of three component models (fig 2⇓). (1) A red
blood cell folate concentration model estimating red blood cell
folate concentration at the time of neural tube closure in
Community Intervention Project participants on the basis of red
blood cell folate concentration in northern and southern
provinces adjusted for consumption of 400 µg of folic acid a
day (if consumed) based on Folic Acid Dosing Trial
dose-response to 400 µg/day folic acid supplementation. (2) A
genotypemodel for estimating the distribution ofMTHFR alleles
among Community Intervention Project participants. (3) A risk
model relating a mother’s estimated red blood cell folate
concentration at the time of her fetus’s neural tube closure and
risk of neural tube defect.
We used a Bayesian approach to update prior assumptions on
the parameters of these models by using the observed
information on time consuming folic acid supplements and
neural tube defect outcomes available in the Community
Intervention Project data. Details on the models, the prior
assumptions on the parameters of the models, and the bayesian
fitting algorithm are given in the statistical appendix.
Prediction of neural tube defect risk from
published red blood cell folate concentration
distributions in US population
We applied the model developed as described above to predict
risk of neural tube defects on the basis of published estimates
of the distribution of red blood cell folate concentrations among
US women before and after folic acid fortification as well as
among pregnant women.33 34 We used published data from the
National Health and Nutrition Examination Survey
(NHANES).33 34 The red blood cell folate concentrations
presented by Pfeiffer et al 2012 and Branum et al 2013 were
generated by a microbiological assay (calibrated with 5’
methylTHF) that was normalized to the microbiological assay
used in the Folic Acid Dosing Trial and the Daly study
(calibrated with folic acid) using the equation: NHANES red
blood cell folate (nmol/L)=(Daly and Folic Acid Dosing Trial
red blood cell folate (nmol/L)×0.7876)+34.2802 (nmol/L)
(personal communication from the data presented in Pfeiffer et
al 2011).33-35 We normalized the pre-fortification folate
concentration data to the microbiological assay in the original
manuscript33; we then converted them by using the same
conversion equation to approximate a match to the Daly et al
data.28We used the adjusted published distributions of red blood
cell folate concentration to generate a modeled population with
a similar distribution of red blood cell folate concentration,33 34
and then we used the modeled associations in the Chinese data
to predict the risk in that modeled US population. Addition
details are provided in the statistical appendix.
Results
The region specific distribution of months consuming folic acid
supplements for Community Intervention Project participants
are shown in supplementary table C. In both regions, a large
proportion of the participants did not take any supplements
(overall 60%). Among those who did take supplements, months
on pills before neural tube closure were fairly evenly distributed
across one to six months. We developed estimates for the
distribution of red blood cell folate concentration at neural tube
closure (day 28 of gestation) among the 228 456 Community
Intervention Project study participants by using the posterior
estimates of the parameters of the concentration model
(supplementary table D). Most (54.4%) of the Community
Intervention Project participants had estimated red blood cell
folate concentrations between 800 and 900 nmol/L; few had
estimated red blood cell folate concentrations less than 500
nmol/L (6.9%) or more than 1500 nmol/L (5.2%)
(supplementary table E). Therefore, we assumed the modeled
association between red blood cell folate and risk of neural tube
defects to be most reliable in a range of estimated red blood cell
folate concentrations between about 500 and 1500 nmol/L.
We used the posterior estimates of the parameters of the risk
model (supplementary table F) to estimate the population level
risk of a neural tube defect at specified concentrations of red
blood cell folate (fig 3⇓, solid blue lines). A result of this
estimation process is the ability to use the 95% uncertainty
intervals surrounding the risk estimates to identify a range of
red blood cell folate concentrations associated with specified
levels of risk of neural tube defects (fig 3⇓ dashed blue lines).
Using this approach, we estimated that the risk of a neural tube
defect affected pregnancywas highest amongwomenwith lower
estimated red blood cell folate concentrations and was
substantially attenuated among those with higher red blood cell
folate concentrations. For example, a risk of 20 neural tube
defects per 10 000 births was associated with an estimated red
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blood cell folate concentration of 580 (95% uncertainty interval
510 to 640) nmol/L, whereas a much lower neural tube defect
risk of 6 per 10 000 was associated with an estimated red blood
cell folate concentration of 1180 (1050 to 1340) nmol/L (table
1⇓). We also used the model to estimate the population level
risk of neural tube defects at specific red blood cell folate
concentrations (table 2⇓). At a red blood cell folate concentration
of 500 nmol/L the estimated risk of a neural tube defect was
25.4 (20.8 to 31.2) per 10 000, whereas at a red blood cell folate
concentration of 1200 nmol/L the estimated risk was more than
fourfold lower at 5.8 (4.6 to 7.1) per 10 000 (table 2⇓).
We also used posterior estimates of the parameters of the risk
model to estimate the risk ratio for a neural tube defect among
MTHFR genotypes. Using this model, we estimated that the
MTHFR TT genotype confers increased risk relative to both the
CC (TT v CC: relative risk 1.49, 95% uncertainty interval 1.33
to 1.70) and CT (TT v CT: 1.28, 1.17 to 1.39) genotypes. In
addition, we estimated that the relative risk for a neural tube
defect is elevated for the CT genotype relative to CC genotype
(CT v CC: 1.17, 1.06 to 1.29).
Our estimates of the association of red blood cell folate
concentration with risk of neural tube defects are consistent
with those observed by Daly and colleagues (fig 3⇓).28 The
posterior estimate of the coefficient of the logistic model relating
the odds of a neural tube defect to the natural logarithm of red
blood cell concentration (supplementary table F) was –1.7 (–2.01
to –1.38). Estimates of risk of neural tube defect among US
women calculated using published red blood cell folate
concentrations as model inputs are shown in supplementary
table G.33 34 We estimated that the risk of neural tube defects in
the fifth centile of red blood cell folate concentrations among
all US women dropped considerably from an estimated 35.9
(28.1 to 46.2) neural tube defects per 10 000 births before
fortification (1988-94) to 14.6 (12.4 to17.0) neural tube defects
per 10 000 births after fortification (2005-10). On the basis of
the distributions of red blood cell folate concentration from
Pfeiffer et al,33 we estimated the population level US
pre-fortification prevalence of neural tube defects to be in the
range of 10.1 to 16.4 per 10 000 births and the post-fortification
prevalence to be in the range of 4.2 to 7.8 per 10 000 births (fig
4⇓). Among pregnant women (all trimesters) after fortification,
moderately increased estimates of risk of neural tube defects
were found below the 10th centile of non-supplement using
pregnant women (estimated risk of 12.9 (11.0 to 15.1) neural
tube defects per 10 000 births).
Discussion
We generated estimates of risk of neural tube defects for a full
range of red blood cell folate concentrations by using
information in the published literature and individual level data
from two studies conducted in China, a community intervention
project and a randomized clinical trial of folic acid
supplementation. The estimated risk of neural tube defects was
highest at lower red blood cell folate concentrations (25.4 (95%
uncertainty interval 20.8 to 31.2) neural tube defects per 10 000
births at 500 nmol/L). The risk was substantially attenuated at
estimated red blood cell folate concentrations above 1000
nmol/L (for example, 6 neural tube defects per 10 000 births at
1180 (1050 to 1340) nmol/L). Our results indicate that a red
blood cell folate concentration of roughly 1000-1300 nmol/L
might achieve optimal prevention of folate sensitive neural tube
defects, with a resulting overall risk of neural tube defects of
about 6 per 10 000. This range could be useful in the
development andmonitoring of folic acid fortification programs.
Association of neural tube defects and red
blood cell folate concentrations in China
compared with Ireland
The modeled associations presented in our study were highly
consistent with the only study in which the association between
measured red blood cell folate concentrations in pregnancy and
risk of neural tube defects was directly assessed (fig 3⇓).28Daly
et al’s study had considerable differences from our project,28
including different racial groups, different typical diets and
corresponding micronutrient intake, a natural diet with no folic
acid intervention compared with the presence of an intervention
with folic acid, directly measured data compared with a
combination of directly measured data and modeled data, and
samples drawn at about 15 weeks of pregnancy compared with
modeled at day 28 of gestation. The fact that the two distinct
studies produced comparable estimates of the associations
between risk of neural tube defects and red blood cell folate
concentration is an indicator of the potential importance of red
blood cell folate concentration as a biomarker for risk of neural
tube defect and provides evidence for the generalizability of
this biomarker across these different populations.
Effect of MTHFR genotype
MTHFR 677 genotype has previously been shown to be
important in determining red blood cell folate concentrations
in response to specific doses of folic acid supplementation and
is associated with risk of neural tube defects across studies.24 25 26
Similarly to the published meta-analyses,25 26 we estimated the
relative risk of a neural tube defect affected pregnancy to be
elevated for the MTHFR TT genotype compared with CC
(relative risk 1.49, 95% uncertainty interval 1.33 to 1.70) and
for TT compared with CT (1.28, 1.17 to 1.39) genotypes. The
approach used in our analysis is based on the assumption that
the effect of the MTHFR T allele on risk of neural tube defect
is associated with its role in causing a decrease in folate
concentrations. Because of our reliance on the use of imputed
estimates of red blood cell folate concentration, we did not deem
it feasible to assess any additional effect of MTHFR on risk of
neural tube defect beyond this. However, increased risk of neural
tube defect associated with theMTHFR TT genotype would be
predicted to be greatest in populations with low folate intake
(for example, ~200 nmol/L decrease in red blood cell folate
concentration from 700 to 500 nmol/L ≈ increase from 14.4 to
25.5 neural tube defects per 10 000 births compared with
decrease from 1400 to 1200 nmol/L ≈ increase from 4.5 to 5.8
neural tube defects per 10 000 births). This is consistent with
other studies of MTHFR that show the strongest effects in
settings with low folate intake.36 Similarly, increasing folate
(natural and/or folic acid) intake resulting in increases in red
blood cell folate concentrations could have the greatest effect
on reducing the number of neural tube defect affected
pregnancies among women with the lowest baseline red blood
cell folate concentrations. Although folate intake and MTHFR
genotype are clearly associated with the risk of neural tube
defects, the consistency of our modeled estimates with those
observed by Daly et al suggests that the observed increased risk
of neural tube defects associated with low folate intake,MTHFR
genotype, or both might be due to their effects on lowering
blood folate concentrations. In populations with a high
percentage of the population with the MTHFR T allele,
additional folate (or folic acid) intake would be needed to
achieve a specific red blood cell folate concentration (such as
1000 nmol/L); however, similar risks of neural tube defects
would be expected for two populations with similar distributions
of red blood cell folate concentrations regardless of genotype.
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If this is the case, measured red blood cell folate concentrations
can potentially be used to predict risk of neural tube defects in
populations without additional information on folate/folic acid
intake or MTHFR genotype as was shown in our analysis (fig
4⇓).
Strengths and limitations
A limitation of our analysis is the lack of measured red blood
cell folate concentrations and MTHFR genotyping among
Community Intervention Project study participants. However,
we were able to use an estimate of the association between folic
acid intake and subsequent red blood cell folate concentrations
observed in an independent Chinese cohort in our analysis.
Several studies have shown similar rates of increase in red blood
cell folate concentrations for folic acid supplementation at about
400 µg/day (supplementary figure F). This observed similarity
increases our confidence in applying the association between
folic acid intake and resulting red blood cell folate
concentrations from the northern Chinese study population to
the southern Chinese study population. However, we
acknowledge that the use of the Folic Acid Dosing Trial based
model relating intake and red blood cell folate concentration in
the Community Intervention Project analysis and the use of
published literature for the southern region’s baseline red blood
cell folate concentrations and genotype frequencies rely on
unverifiable, although reasonable, assumptions. The bayesian
modeling approach used in this analysis gave us a mechanism
to incorporate uncertainty associated with these assumptions
into the final estimates.
Another limitation of this analysis is that we applied estimated
red blood cell folate concentrations from women who were not
pregnant (Folic Acid Dosing Trial) to those who were 28 days
pregnant (Community Intervention Project). This assumes that
red blood cell folate concentrations do not change substantially
during the first 28 days after conception. Without
supplementation, folate concentrations have been reported to
fall as pregnancy advances past the first trimester, with
substantial reductions by the third trimester,37 38 presumably due
to hemodilution.Whether changes in blood folate concentrations
or folic acid metabolism occur in the first 28 days compared
with the immediate pre-pregnancy time period is not known.
The similarity between our analysis and the Daly et al analysis
(mean gestational age 15 weeks)28 suggests that no dramatic
shifts occur. As we intend the model to be used to predict risk
of neural tube defects in a population with red blood cell folate
concentration collected from non-pregnant women, the fact that
our findings and those of Daly et al are in such close agreement
is reassuring.28
A major strength of our study is the large sample size of the
observed data on which the model’s estimates were based: 228
456 births and 250 neural tube defects. All subtypes of neural
tube defects were included in the Community Intervention
Project and in Daly et al,1 28 allowing for comparison of the
overall rates of neural tube defects. The inclusion of all neural
tube defects, as well as neural tube defects resulting in
pregnancy loss and terminations, is important when evaluating
the presented estimates of red blood cell folate concentration
and risk of neural tube defects and comparing the prevalences
of neural tube defects with those of other populations. The
availability of high quality compliance data for the folic acid
supplement taking history of participating women allowed
adjustment of the estimated red blood cell folate concentrations.
Furthermore, our assessment of alternative data inputs (see
statistical appendix) indicated that the assumptions about the
risk model parameters and the adequacy of the assumed
concentration model had a marginal effect on the estimates
presented in this analysis. The estimates derived in our modeling
approach, which used no direct information from results of Daly
et al, were consistent with the findings from that Irish cohort,
thereby providing independent support for our general modeling
assumptions and supporting the generalizability of our estimated
results, at least among the populations being compared. Finally,
we were able to use published red blood cell folate
concentrations from the US population before and after
fortification to predict risks of neural tube defects consistent
with published prevalence estimates. Taken together, this
suggests that distributions of red blood cell folate concentration
can be used to predict the risk of folate sensitive neural tube
defects in some populations and may be useful in establishing
the need for and success of folic acid intervention programs.
Implications for neural tube defect prevention:
application of model
Neural tube defects are a complex group of birth defects that
do not share a single cause and not all are preventable with
adequate folic acid intake.12Distributions of red blood cell folate
concentration predict only the risk of neural tube defects that
are folate sensitive and amenable to prevention by folic acid; if
the associations presented here are accurate, distributions of red
blood cell folate concentrations should predict risk of neural
tube defects independently of other causes of neural tube defects.
Periconceptional folic acid supplementation and food
fortification programs have been observed to reduce the
prevalence of neural tube defects by about 30-80%, depending
on several factors such as the level of folic acid fortification
and background prevalence of neural tube defects.1-3 5-9 27Overall,
a prevalence of neural tube defects lower than 5-6 per 10 000
births has not been achieved consistently during intervention
studies or after folic acid fortification,1-3 5-9 27 so we might
reasonably assume that the lowest feasible prevalence of neural
tube defects obtainable through folic acid based interventions
is approximately 5-6 per 10 000 births.
Implications for United States
Before fortification of food with folic acid (1995-96), the
prevalence of neural tube defects in the United States was
estimated to be 10.8 per 10 000 births (fig 4⇓).39 Applying the
estimated risk model presented here to published adjusted
NHANES red blood cell folate concentrations, we estimate a
predicted median pre-fortification (1988-94 women and girls
aged >4 years) prevalence of neural tube defects of 13 (95%
uncertainty interval 10.1 to 16.4) per 10 000 births. Parker and
colleagues (2010) reported a post-fortification (2004-06)
prevalence of 6.8 neural tube defects per 10 000 births in active
surveillance programs (2.23 (95% confidence interval 2.07 to
2.41) per 10 000 for anencephaly, 3.72 (3.52 to 3.94) for spina
bifida without anencephaly, and 0.84 (0.74 to 0.94) for
encephalocele).39 40 Using the published adjusted NHANES
distributions of red blood cell folate concentration,33 35 and the
risk model developed in this analysis, we estimated a median
post-fortification (2005-10, women and girls aged >4 years)
prevalence of 5.9 (95% uncertainty interval 4.2 to 7.8) neural
tube defects per 10 000 births. Our overall prevalence estimates
for neural tube defects (fig 4⇓) are therefore consistent with the
estimates in the published literature based on US surveillance
systems before and after fortification.39 40 Pre-fortification, the
10th centile of women had a substantially increased risk of
neural tube defect (~25 neural tube defects per 10 000) and the
50th centile of the folate concentration distribution among all
US women was below the likely optimal blood folate
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concentration range of 1000-1300 nmol/L; post-fortification,
all but the 10th centile of all pregnant women in their first
trimester were at or above the estimated optimal range
(supplementary table G).
Additional studies are needed to characterize the portion of US
women of reproductive age with insufficient red blood cell folate
concentration and to determine whether they would benefit from
additional folate/folic acid intake. Encouragingly for US
prevention efforts in the post-folic acid fortification era, a large
percentage of pregnant US women have red blood cell folate
concentrations at or above those associated with low risk of
neural tube defects, even in the absence of folic acid supplement
use. Given the high rate of unplanned pregnancies in the United
States (~50%),41 the fact that the neural tube closes by day 28
of gestation (often before a woman confirms that she is
pregnant), and the low levels of supplement use among women
of childbearing age (~32%),42 a subset of non-supplement using
women might still be at increased risk of folate preventable
neural tube defects (supplementary table G).
Implications for other countries
The low rates of compliance with recommendations on folic
acid supplementation have also been documented in many
non-US populations.43-46 A recent study of more than 400 000
women in the United Kingdom found that only 31% of women
overall and 51% of women with a previous neural tube defect
affected pregnancy consumed a folic acid supplement before
their current pregnancy.43 This low rate of compliance with
recommendations even among those at high risk is concerning
given the lack of mandatory folic acid fortification in the United
Kingdom. The model presented here shows that modest shifts
in red blood cell folate concentrations among those with the
lowest concentrations produce the greatest reduction in risk of
neural tube defect. We estimate that the risk of neural tube
defects in the fifth centile of red blood cell folate concentrations
among all US women dropped considerably from a
pre-fortification (1988-94) estimated 35.9 (95% uncertainty
interval 28.1 to 46.2) neural tube defects per 10 000 births to a
post-fortification (2005-10) 14.6 (12.4 to17.0) neural tube
defects per 10 000 births with a moderate 300 nmol/L increase
in blood folate concentration. This suggests that food
fortification programs that reach the most at risk populations
with a moderate intake of folic acid have the best potential for
impact on the prevalence of neural tube defects, especially in
settings with low compliance with recommendations on
pre-pregnancy folic acid supplementation.
Unanswered questions and future research
Folic acid intake
How much natural food folate and/or folic acid intake is
necessary to achieve red blood cell folate concentrations in the
1000-1300 nmol/L range in any given person or population is
unknown. In the Folic Acid Dosing Trial in northern China,15 24
people consuming 100 µg/day in addition to usual diet (which
is relatively low in other sources of folate) did not achieve a red
blood cell folate concentration of 1000 nmol/L by the end of
the six month supplementation trial.24 Those with the CC and
CT genotypes who consumed 400 µg/day reached a red blood
cell folate concentration of 1000 nmol/L between three and six
months of supplementation, whereas those with the TT genotype
did not achieve a geometric mean red blood cell folate
concentration of 1000 nmol/L by the six month sample.24
However, the geometric mean red blood cell folate concentration
of theMTHFR TT group did surpass the 906 nmol/L threshold
used by Daly et al,28 and it continued to rise after six months of
supplementation. Other studies of folic acid supplementation
at 400 µg/day dosage have found that red blood cell folate
concentrations reached 1000 nmol/L after approximately two
to six months of supplementation depending on baseline
concentrations among other factors (supplementary figure F).16-23
A recent study showed that a steady state of red blood cell folate
concentrations was not achieved until after 12 months of
supplementation (1 mg/day dose in older adults), and whether
a steady state is reached sooner or later for lower folic acid
dosages is unclear.47 The red blood cell folate concentration
associated with a 1000 µg/day dose for 12-24 months was
between 3010 and 3430 nmol/L in New Zealand participants
aged 65 years and older.47 In the United States, the median folic
acid intake from enriched cereal grain product (fortification)
has been estimated to be 138 µg/day and that from both enriched
cereal grain product and ready to eat cereal to be 274 µg/day.48
Pregnant non-supplement users might consume an amount of
folic acid similar to that of the general population, which would
contribute to the observed elevated red blood cell folate
concentrations and the observed reductions in neural tube defects
after fortification.34 In determining howmuch folate and/or folic
acid needs to be consumed to reach a red blood cell folate
concentration in the “optimal” range, determining the baseline
folate concentrations, the length of time before neural tube
closure, and MTHFR genotype, among other factors, will be
important. If supplementation is started more than six months
before pregnancy or folic acid is ingested regularly as part of
food fortification, these data suggest that a folic acid dosage of
less than 400 µg/day (but greater than 100 µg/day) in addition
to a usual diet could be sufficient to prevent most folate sensitive
neural tube defects in many populations of women.
Determination of the range of natural food folate and/or folic
acid necessary to achieve any proposed optimal concentration
in different populations is a subject for future research projects.
We are unaware of any adverse outcomes associated with the
moderate red blood cell folate concentrations in the proposed
optimal range (~1000-1300 nmol/L). Themodeled associations
presented here provide evidence that red blood cell folate
concentrations in excess of 1300-1500 nmol/L provide little
additional benefit for prevention of neural tube defects, so
substantial benefit in reducing risk of neural tube defect might
be achieved by folic acid intakes well below the 1000 µg/day
tolerable upper intake level.
Other populations
Information about folate status, neural tube defect rates, and
changes in red blood cell folate concentration in response to
folic acid intake in many regions of the world is very limited,
especially in African countries. Although the associations
between risk of neural tube defect and red blood cell folate
concentrations are remarkably similar between these Irish,
Chinese, and overall US (majority of European decent)
populations, whether they also apply to other populations is not
known.
Plasma or serum folate concentrations
Many researchersmeasure serum or plasma folate concentrations
to monitor folate status. Unfortunately, Daly et al report that
they did not present a plasma folate concentration model owing
to the fact that plasma folate is a very short term measure of
blood folate concentration, and red blood cell folate
concentrations (collected at 15 weeks’ gestation) were
considered to be most similar to those to which the fetus was
exposed.28 Women with plasma folate concentrations above
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15.9 nmol/L had an associated risk of 9 (95% confidence interval
5 to 17) neural tube defects per 10 000.28 In the United States
after fortification, the 25th centile of women had serum folate
concentrations of 29.5 nmol/L, and the 50th centile had serum
folate concentration of 43.5 nmol/L (2005-10 NHANES >4
years of age, serum folate concentrations unadjusted for assay
difference; 25th and 50th centile red blood cell folate
concentrations 1050 and 1379 nmol/L, respectively, adjusted
for assay difference; supplementary table F).33 Additional
research is needed to explore the utility of using plasma or serum
folate concentrations to predict the risk of neural tube defects
and to monitor prevention programs.
Conclusions
We provide evidence that red blood cell folate concentration is
a generalizable marker for risk of neural tube defects and that
setting “optimal” or target population red blood cell folate
concentrations will be useful in assessing the need for and
monitoring the success of programs for the prevention of folate
sensitive neural tube defects. Our results indicate that risk of
neural tube defects is substantially attenuated in populations
with higher red blood cell folate concentrations.
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What is already known on this topic
If taken regularly before pregnancy, 400 μg/day of folic acid reduces a woman’s risk of a neural tube defect affected pregnancy by up
to 85%
Increased intake of folate and/or folic acid increases red blood cell (RBC) folate concentrations, so these might be a reasonable biomarker
for risk of neural tube defects in the establishment and monitoring of prevention programs
A study in an Irish population showed that the risk of a neural tube defect affected pregnancy increased 10-fold as RBC folate
concentrations decreased
What this study adds
A generalizable dose-response relation exists between RBC folate concentrations and risk of neural tube defects in both Irish and
Chinese women despite differences in genetic background and diet
RBC folate concentration distributions alone can be used to predict prevalence of neural tube defects and change in prevalence associated
with folic acid food fortification
RBC folate concentrations above about 1000 nmol/L are consistent with optimal reduction in risk of folate sensitive neural tube defects,
but limited additional risk reductions are predicted with concentrations above about 1300 nmol/L
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Tables
Table 1| Estimated red blood cell folate concentrations associated with specified levels of risk of neural tube defect among participants in
Community Intervention Project






Estimates were derived using estimated parameters of neural tube defect risk model; details on model, underlying assumptions, and methods used to develop
estimates are provided in supplementary material.
*Median (rounded to nearest 10) of posterior distribution for possible values of red blood cell folate concentration associated with specified level of neural tube
defect risk.
†Lower value of this interval is 2.5th centile of posterior distribution for possible values of red blood cell folate concentration associated with specified level of
neural tube defect risk; upper value is 97.5th centile of distribution.
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Table 2| Estimated risk of neural tube defect per 10 000 births for specified red blood cell folate concentrations among participants in
Community Intervention Project











Estimates were derived using estimated parameters of neural tube defect risk model; details on model, underlying assumptions, and methods used to develop
estimates are provided in supplementary material.
*Median of posterior distribution of possible values for neural tube defect risk associated with specified red blood cell folate concentration.
†Lower value of interval is 2.5th centile of posterior distribution for possible values of neural tube defect risk associated with specified red blood cell folate
concentration; upper value is 97.5th centile of distribution.
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Figures
Fig 1 Relation between folic acid intake, blood folate concentration, and risk of neural tube defects. a: Many studies have
shown that folic acid intake from multivitamin and folic acid only supplements (common doses between 200 and 5000
µg/day) in the periconceptional period (before neural tube closure at day 28) reduces risk of neural tube defects in those
pregnancies. b: Controlled folic acid intake studies show that folic acid increases blood folate concentrations; these studies
have shown that absolute concentration after folic acid intake is dependent on dose of folic acid supplements, length of
time supplement is consumed, baseline folate concentration, and genetic variation in folate metabolism (notablyMTHFR677).
c: Single study of blood folate concentration (red blood cell (RBC) and plasma) during pregnancy (mean gestational age
15 weeks) showed inverse dose-response with risk of neural tube defects in offspring. Study reported here used information
from existing data sources to build a statistical model to predict association between RBC folate concentration at time of
neural tube closure (embryologic day 28) and risk of neural tube defects
Fig 2Genotype, concentration, and risk model components used to assess association between red blood cell (RBC) folate
concentration and risk of neural tube defects among Community Intervention Project participants. Genotypemodel:MTHFR
genotype frequencies have been shown to be different in northern (36% TT in Folic Acid Dosing Trial) and southern Chinese
populations (8% TT).20 25 26 Each person was assigned a probability of having a specific genotype. RBC folate concentration
model: RBC folate concentration at time of neural tube closure was estimated on basis of region of residence (northern v
southern), probable genotype, and folic acid supplementation history. Substantial regional differences in diet have been
previously described, with northern regions having less natural folate intake and lower RBC folate concentrations.1 29-31 As
a result, the concentration model included a term reflecting regional differences in baseline RBC concentration. Neural tube
defect risk model: risk of neural tube defects associated with RBC folate concentrations was estimated for Community
Intervention Project participants on basis of observed neural tube defect occurrence and estimated RBC folate concentration
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Fig 3 Estimated risk of neural tube defect per 10 000 births by red blood cell (RBC) folate concentration (nmol/L) at time
of neural tube closure among participants in Community Intervention Project and observed values of neural tube defect
risk at measured RBC folate concentrations (nmol/L) reported by Daly et al (1995). Estimates were derived using estimated
parameters of neural tube defect risk model to predict neural tube defect risk at specified RBC folate concentrations. Solid
blue line is median of posterior distribution of possible values of neural tube defect risk at given concentration; dashed blue
lines reflect 95% uncertainty interval for estimate. Lower value of this interval is 2.5th centile of posterior distribution of
possible values for neural tube defect risk; upper value is 97.5th centile. Estimated time of closure of fetal neural tube was
date of initiation of last reported menstrual cycle plus 42 days
Fig 4 Using model developed with Chinese data to predict prevalence of neural tube defects from population level red blood
cell (RBC) folate concentrations in US population before and after mandatory folic acid fortification. *RBC folate concentrations
from Pfeiffer et al33 (supplementary table D, female participants 4 years and older during pre-fortification period, NHANES
1988-94; supplementary table F, total female participants aged 4 years and older, NHANES 2005-10). Published RBC
folate concentration centiles were normalized to method used in papers by both Daly and Hao, using standardizing equations
generated from Pfeiffer 201135: NHANES RBC folate (nmol/L)=(Dublin RBC folate (nmol/L)×0.7876)+34.2802 (nmol/L)
(personal communication). These adjusted RBC folate concentrations were used to generate a modeled population with a
similar distribution of RBC folate concentration; modeled associations in Chinese data were then used to predict risk in that
modeled US population. †Neural tube defect prevalence for US (1994-95) just before start of mandatory folic acid fortification.39
‡Neural tube defect prevalence for US (2004-06) after implementation of mandatory folic acid fortification40
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